Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)

About this update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A

[{"type":"text","content":"SHANGHAI, Sept. 24, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK), a leading innovative global pharmaceutical company focused on scientific and technological innovation, announced today that it has entered into an exclusive license agreement with Glenmark Specialty S.A. (GSSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd., which is a research-led, global pharmaceutical company, for Hengrui's independently developed HER2-targeting ADC, Trastuzumab Rezetecan (SHR-A1811).","length":503,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Hengrui has granted Glenmark exclusive rights to develop and commercialize Trastuzumab Rezetecan worldwide, excluding Mainland China, the Hong Kong SAR, the Macao SAR, Taiwan Region, USA, Canada, Europe, Japan, Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan and Uzbekistan. Glenmark will pay Hengrui an upfront payment of US$18 million. Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion. Based on the net sales of Trastuzumab Rezetecan within the licensed territory, Glenmark will pay corresponding royalties to Hengrui.","length":660,"tagName":"p"},{"type":"text","content":"Jo Feng, President of Hengrui Pharma, said:","length":43,"tagName":"p"},{"type":"text","content":""Facing the major global challenge of cancer treatment, Hengrui has over the years accelerated the research and development of cutting-edge innovative therapies such as ADCs, and is committed to addressing clinical treatment challenges and meeting unmet medical needs. This collaboration with Glenmark is a significant step in Hengrui's ongoing strategy to deepen its presence in emerging markets. We look forward to working together to enhance the accessibility of innovative therapies and to bring new hope to patients in more countries and regions."","length":566,"tagName":"p"},{"type":"text","content":"Glenn Saldanha, Chairman and Managing Director of Glenmark, said:","length":65,"tagName":"p"},{"type":"text","content":""We are delighted to collaborate with Hengrui and build on the scientific momentum of Trastuzumab Rezetecan (SHR-A1811) as we continue expanding our oncology pipeline and leadership. This partnership aligns strongly with our strategy to bring differe...

More updates from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A